Form 8-K - Current report:
SEC Accession No. 0001193125-20-141074
Filing Date
2020-05-13
Accepted
2020-05-13 07:43:46
Documents
13
Period of Report
2020-05-13
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d928518d8k.htm   iXBRL 8-K 27275
2 EX-99.1 d928518dex991.htm EX-99.1 11636
  Complete submission text file 0001193125-20-141074.txt   166587

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vnda-20200513.xsd EX-101.SCH 3105
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE vnda-20200513_lab.xml EX-101.LAB 18138
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vnda-20200513_pre.xml EX-101.PRE 11431
14 EXTRACTED XBRL INSTANCE DOCUMENT d928518d8k_htm.xml XML 3372
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

IRS No.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34186 | Film No.: 20871047
SIC: 2834 Pharmaceutical Preparations